Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
Introduction: Hepatitis C virus (HCV) is the second major cause of death in Pakistan. Previously, interferon-based regimens were considered highly recommended therapy for HCV patients. Since 2015, interferon-based therapy has been replaced with interferon-free therapy also known as Direct Acting Ant...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023033765 |
| _version_ | 1797815571038863360 |
|---|---|
| author | Hafiza Arooba Riaz Dur E. Nishwa Ameer Fatima Braira Wahid Akhtar Ali Babita Kumari Muhammad Idrees |
| author_facet | Hafiza Arooba Riaz Dur E. Nishwa Ameer Fatima Braira Wahid Akhtar Ali Babita Kumari Muhammad Idrees |
| author_sort | Hafiza Arooba Riaz |
| collection | DOAJ |
| description | Introduction: Hepatitis C virus (HCV) is the second major cause of death in Pakistan. Previously, interferon-based regimens were considered highly recommended therapy for HCV patients. Since 2015, interferon-based therapy has been replaced with interferon-free therapy also known as Direct Acting Antiviral (DAA) drugs. The treatment response of interferon-free regimens has been reported as highly effective treatment option with more than 90% sustained virological response (SVR) in chronic HCV infected patients in western countries of the world. Objective: This study aims to analyze the treatment response of DAA drugs in HCV-infected Pakistani population with liver cirrhosis. Methodology: We collected the total 94 sample of the HCV infected patients, from June 2020 to September 2020. Forty-six (46) patients were cirrhotic, and forty-eight (48) patients were non-cirrhotic. Data was analyzed using IBM SPSS version 21 software. Conclusion: The findings of our study suggest that the response rate was 82.60% in HCV cirrhotic patients and 68.75% in HCV non-cirrhotic patients. Our study showed that overall treatment response was independent of age and gender. We also observed some adverse effects such as hepatocellular carcinoma, portosystemic encephalopathy (PSE), spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), upper gastrointestinal bleeding (UGIB), ascites, among patients following treatment with interferon-free regimens. |
| first_indexed | 2024-03-13T08:24:49Z |
| format | Article |
| id | doaj.art-5fde9f91f27246ffa47a8fadde42dcce |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-13T08:24:49Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-5fde9f91f27246ffa47a8fadde42dcce2023-05-31T04:46:50ZengElsevierHeliyon2405-84402023-05-0195e16169Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosisHafiza Arooba Riaz0Dur E. Nishwa1Ameer Fatima2Braira Wahid3Akhtar Ali4Babita Kumari5Muhammad Idrees6Department of Life Sciences, School of Sciences, University of Management and Technology, Lahore, PakistanDepartment of Life Sciences, School of Sciences, University of Management and Technology, Lahore, PakistanHepatobiliary and Gastroenterology Unit, Sheikh Zayed Hospital, Lahore, PakistanDepartment of Life Sciences, School of Sciences, University of Management and Technology, Lahore, Pakistan; Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3168, Australia; Corresponding author. Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3168, Australia.School of Agriculture and Food, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, VIC, 3010, AustraliaDepartment of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3168, AustraliaDivision of Molecular Virology, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, PakistanIntroduction: Hepatitis C virus (HCV) is the second major cause of death in Pakistan. Previously, interferon-based regimens were considered highly recommended therapy for HCV patients. Since 2015, interferon-based therapy has been replaced with interferon-free therapy also known as Direct Acting Antiviral (DAA) drugs. The treatment response of interferon-free regimens has been reported as highly effective treatment option with more than 90% sustained virological response (SVR) in chronic HCV infected patients in western countries of the world. Objective: This study aims to analyze the treatment response of DAA drugs in HCV-infected Pakistani population with liver cirrhosis. Methodology: We collected the total 94 sample of the HCV infected patients, from June 2020 to September 2020. Forty-six (46) patients were cirrhotic, and forty-eight (48) patients were non-cirrhotic. Data was analyzed using IBM SPSS version 21 software. Conclusion: The findings of our study suggest that the response rate was 82.60% in HCV cirrhotic patients and 68.75% in HCV non-cirrhotic patients. Our study showed that overall treatment response was independent of age and gender. We also observed some adverse effects such as hepatocellular carcinoma, portosystemic encephalopathy (PSE), spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), upper gastrointestinal bleeding (UGIB), ascites, among patients following treatment with interferon-free regimens.http://www.sciencedirect.com/science/article/pii/S2405844023033765HCVInterferonDirect acting antiviral drugsLiver cirrhosisHepatotoxicity |
| spellingShingle | Hafiza Arooba Riaz Dur E. Nishwa Ameer Fatima Braira Wahid Akhtar Ali Babita Kumari Muhammad Idrees Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis Heliyon HCV Interferon Direct acting antiviral drugs Liver cirrhosis Hepatotoxicity |
| title | Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis |
| title_full | Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis |
| title_fullStr | Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis |
| title_full_unstemmed | Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis |
| title_short | Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis |
| title_sort | risk of adverse outcomes following treatment with direct acting antiviral drugs in hcv infected patients with liver cirrhosis |
| topic | HCV Interferon Direct acting antiviral drugs Liver cirrhosis Hepatotoxicity |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023033765 |
| work_keys_str_mv | AT hafizaaroobariaz riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT durenishwa riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT ameerfatima riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT brairawahid riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT akhtarali riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT babitakumari riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis AT muhammadidrees riskofadverseoutcomesfollowingtreatmentwithdirectactingantiviraldrugsinhcvinfectedpatientswithlivercirrhosis |